Page 8 - SFHN March 2018

Consumers, Healthcare Orgs Unaligned

On Value-Based Drug Pricing:

BDO/NEJM Catalyst Survey

When it comes to aligning care outcomes with pricing, consumers and health- BDO’s quick take: The findings underline that while public pressure to curb
care providers are, well… unaligned, a new survey from BDO and the New drug prices continues to mount, the tactics of doing so realistically have not yet
England Journal of Medicine (NEJM) Catalyst reveals. been realized. We believe this is because of continued high valuations paired with
Most patients (74 percent) are interested in outcomes-based drug pricing, yet pharmaceutical companies that are under more pressure to maximize the prof-
the majority of healthcare organizations (59 percent) are not yet working with itability of a limited number of lucrative products. This provides little incentive
drug manufacturers to track care outcomes—and have no plans to do so. Only 8 for pharma to come to the table on outcomes-based pricing.
percent of patients, meanwhile, said they were not interested at all in outcomes- The December survey polled the NEJM Catalyst Insights Council, a qualified
based drug pricing, while 11 percent of healthcare organizations said they are cur- group of healthcare executives, clinical leaders, and clinicians at organizations
rently working with drug manufacturers to track care outcomes. directly involved in care delivery. Respondents also said they expect innovative
mergers like the CVS-Aetna deal—along with new market entrants—to continue
to disrupt healthcare.
PATIENT INTEREST IN VALUE-BASED DRUG PRICING Eighty-one percent expect such mergers to continue disrupting the industry
over the next three years. When asked which companies are expected to have the
most significant impact on the industry during that time, CVS-Aetna came first,

followed by Amazon, Optum-DaVita, Google, and Apple.

IMPACT OF NEW ENTRANTS IN HEALTHCARE INDUSTRY

STATUS OF WORKING WITH DRUG COMPANIES
TO TRACK OUTCOMES
BDO’s quick take: CVS-Aetna was a watershed moment in healthcare—one that
will certainly unleash an avalanche. We see such deals giving consumers greater

visibility into their care options and costs, offering them more convenient, effec-
tive, and streamlined services. But the potential for Amazon and other tech giants
to disrupt is even greater. Amazon could purchase a health insurer (or any health-
care company) tomorrow—turning the traditional care delivery and pricing
model upside down and forcing other healthcare organizations to reimagine their
business models to remain competitive.

Visit the BDO Knows Healthcare Blog https://www.bdo.com/blogs/healthcare for

$
#
$
#

! !
!

resources and discussions on the latest issues impacting the healthcare industry.
Their South Florida healthcare leaders are ready to address your

complex and unique needs: Alfredo Cepero, Managing Partner,

"

305-420-8006/ acepero@bdo.com or Angelo Pirozzi, Partner,
646-520-2870 / apirozzi@bdo.com.
Holy Cross
Hospital Names
2017 Director of
the Year

Alissa V. Fuller, Pharm.D., director of
pharmacy services at Holy Cross Hospital,
has been named the 2017 Director of the
Year. Fuller began her career at Holy Cross
Hospital in 1992 as a clinical pharmacy Alissa V. Fuller with Dr. Patrick A. Taylor,
specialist. Since 2014, the Delray Beach Holy Cross Hospital President and CEO
resident has served as director of pharma-
cy at the non-profit hospital where she manages and oversees more than 37 associates
at the 24-hour hospital pharmacy and outpatient cancer center pharmacy. Fuller was
recognized for her willingness to embrace change and for taking on new administra-
tive responsibilities successfully. She was lauded for her strong focus on customer
service and for always bringing back her new knowledge to her areas of responsibility
in order to respond to the ever-changing needs of the health care industry.

8 March 2018 southfloridahospitalnews.com South Florida Hospital News